Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, Natalie Maimon, Avivit Peer, Avivit Neumann, Hans Hammers, Mario Eisenberger, Victoria Sinibaldi, Roberto Pili, Henry Hayat, Svetlana Kovel, Avishay Sella, Ben Boursi, Rony Weitzen, Wilmosh Mermershtain, Keren Rouvinov, Raanan Berger, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Obesity, smoking, hypertension, and diabetes are risk factors forrenal cell carcinomadevelopment.Theirpresence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatment in metastatic renal cell carcinoma (mRCC). Methods. An international multicenter retrospective study of sunitinib-treated mRCC patients was performed. Multivariate analyses were performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors. Results. Between 2004 and 2013, 278 mRCC patients were treated with sunitinib: 59 were active smokers, 67 were obese, 73 were diabetic, and 165 had pretreatment hypertension. Median progression-free survival (PFS) was 9 months, and overall survival (OS) was 22 months. Factors associated with PFS were smoking status (past and active smokers: hazard ratio [HR]: 1.17, p=.39; never smokers: HR: 2.94, p

Original languageEnglish (US)
Pages (from-to)51-60
Number of pages10
JournalOncologist
Volume19
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Smoking
Hypertension
Survival
Multicenter Studies
Body Mass Index
Multivariate Analysis
Retrospective Studies
Obesity
sunitinib
Neoplasms

Keywords

  • Active smoking
  • Metastatic renal cell carcinoma
  • Outcome
  • Sunitinib treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib. / Keizman, Daniel; Gottfried, Maya; Ish-Shalom, Maya; Maimon, Natalie; Peer, Avivit; Neumann, Avivit; Hammers, Hans; Eisenberger, Mario; Sinibaldi, Victoria; Pili, Roberto; Hayat, Henry; Kovel, Svetlana; Sella, Avishay; Boursi, Ben; Weitzen, Rony; Mermershtain, Wilmosh; Rouvinov, Keren; Berger, Raanan; Carducci, Michael A.

In: Oncologist, Vol. 19, No. 1, 2014, p. 51-60.

Research output: Contribution to journalArticle

Keizman, D, Gottfried, M, Ish-Shalom, M, Maimon, N, Peer, A, Neumann, A, Hammers, H, Eisenberger, M, Sinibaldi, V, Pili, R, Hayat, H, Kovel, S, Sella, A, Boursi, B, Weitzen, R, Mermershtain, W, Rouvinov, K, Berger, R & Carducci, MA 2014, 'Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib', Oncologist, vol. 19, no. 1, pp. 51-60. https://doi.org/10.1634/theoncologist.2012-0335
Keizman, Daniel ; Gottfried, Maya ; Ish-Shalom, Maya ; Maimon, Natalie ; Peer, Avivit ; Neumann, Avivit ; Hammers, Hans ; Eisenberger, Mario ; Sinibaldi, Victoria ; Pili, Roberto ; Hayat, Henry ; Kovel, Svetlana ; Sella, Avishay ; Boursi, Ben ; Weitzen, Rony ; Mermershtain, Wilmosh ; Rouvinov, Keren ; Berger, Raanan ; Carducci, Michael A. / Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib. In: Oncologist. 2014 ; Vol. 19, No. 1. pp. 51-60.
@article{95dd03da82394539a8bde49b0d0d4365,
title = "Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib",
abstract = "Obesity, smoking, hypertension, and diabetes are risk factors forrenal cell carcinomadevelopment.Theirpresence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatment in metastatic renal cell carcinoma (mRCC). Methods. An international multicenter retrospective study of sunitinib-treated mRCC patients was performed. Multivariate analyses were performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors. Results. Between 2004 and 2013, 278 mRCC patients were treated with sunitinib: 59 were active smokers, 67 were obese, 73 were diabetic, and 165 had pretreatment hypertension. Median progression-free survival (PFS) was 9 months, and overall survival (OS) was 22 months. Factors associated with PFS were smoking status (past and active smokers: hazard ratio [HR]: 1.17, p=.39; never smokers: HR: 2.94, p",
keywords = "Active smoking, Metastatic renal cell carcinoma, Outcome, Sunitinib treatment",
author = "Daniel Keizman and Maya Gottfried and Maya Ish-Shalom and Natalie Maimon and Avivit Peer and Avivit Neumann and Hans Hammers and Mario Eisenberger and Victoria Sinibaldi and Roberto Pili and Henry Hayat and Svetlana Kovel and Avishay Sella and Ben Boursi and Rony Weitzen and Wilmosh Mermershtain and Keren Rouvinov and Raanan Berger and Carducci, {Michael A}",
year = "2014",
doi = "10.1634/theoncologist.2012-0335",
language = "English (US)",
volume = "19",
pages = "51--60",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

AU - Keizman, Daniel

AU - Gottfried, Maya

AU - Ish-Shalom, Maya

AU - Maimon, Natalie

AU - Peer, Avivit

AU - Neumann, Avivit

AU - Hammers, Hans

AU - Eisenberger, Mario

AU - Sinibaldi, Victoria

AU - Pili, Roberto

AU - Hayat, Henry

AU - Kovel, Svetlana

AU - Sella, Avishay

AU - Boursi, Ben

AU - Weitzen, Rony

AU - Mermershtain, Wilmosh

AU - Rouvinov, Keren

AU - Berger, Raanan

AU - Carducci, Michael A

PY - 2014

Y1 - 2014

N2 - Obesity, smoking, hypertension, and diabetes are risk factors forrenal cell carcinomadevelopment.Theirpresence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatment in metastatic renal cell carcinoma (mRCC). Methods. An international multicenter retrospective study of sunitinib-treated mRCC patients was performed. Multivariate analyses were performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors. Results. Between 2004 and 2013, 278 mRCC patients were treated with sunitinib: 59 were active smokers, 67 were obese, 73 were diabetic, and 165 had pretreatment hypertension. Median progression-free survival (PFS) was 9 months, and overall survival (OS) was 22 months. Factors associated with PFS were smoking status (past and active smokers: hazard ratio [HR]: 1.17, p=.39; never smokers: HR: 2.94, p

AB - Obesity, smoking, hypertension, and diabetes are risk factors forrenal cell carcinomadevelopment.Theirpresence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatment in metastatic renal cell carcinoma (mRCC). Methods. An international multicenter retrospective study of sunitinib-treated mRCC patients was performed. Multivariate analyses were performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors. Results. Between 2004 and 2013, 278 mRCC patients were treated with sunitinib: 59 were active smokers, 67 were obese, 73 were diabetic, and 165 had pretreatment hypertension. Median progression-free survival (PFS) was 9 months, and overall survival (OS) was 22 months. Factors associated with PFS were smoking status (past and active smokers: hazard ratio [HR]: 1.17, p=.39; never smokers: HR: 2.94, p

KW - Active smoking

KW - Metastatic renal cell carcinoma

KW - Outcome

KW - Sunitinib treatment

UR - http://www.scopus.com/inward/record.url?scp=84892585606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892585606&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0335

DO - 10.1634/theoncologist.2012-0335

M3 - Article

VL - 19

SP - 51

EP - 60

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -